+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data



Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data



Journal of Microbiology, Immunology, and Infection 2018



Treatment of chronic hepatitis C (CHC) has entered a new era since the introduction of direct-acting antiviral agents (DAAs). Numerous clinical trials have shown that treatment response as well as tolerability of DAAs are superior to those of conventional therapy with pegylated interferon and ribavirin. However, the results of clinical trials may not be directly applied to real-world practice. Therefore our study tried to investigate the effectiveness of various DAA regimens in Taiwanese patients with chronic hepatitis C. We performed a retrospective study on 400 CHC patients. The primary endpoint was undetectable HCV RNA (an HCV RNA level of <25 IU/mL) at 12 weeks posttreatment (SVR12). The results were stratified by different DAAs and HCV genotypes. Genotype 1b was the major genotype (297, 74.3%), followed by genotype 2 (65, 16.3%). The patients were treated according to HCV genotype, clinical practice and reimbursement guidelines. The SVR12 rates of 57 patients treated with sofosbuvir and ribavirin, 107 treated with ledipasvir/sofosbuvir with or without ribavirin, 60 treated with daclatasvir/asunaprevir with or without ribavirin, 129 treated with ombitasvir/paritaprevir/ritonavir/dasabuvir with or without ribavirin, 12 treated with sofosbuvir/daclatasvir with or without ribavirin, and 35 treated with elbasvir/grazoprevir were 98.2%, 97.2%, 85.0%, 97.7%, 100.0%, and 100.0%, respectively. The overall SVR12 rates in our study were comparable with those in previous pivotal trials. DAAs are generally safe. The interaction of HBV and HCV during DAA therapy and the observation of de novo HCC development and HCC recurrence during or after DAAs warrants additional studies.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065898455

Download citation: RISBibTeXText

PMID: 30316726

DOI: 10.1016/j.jmii.2018.09.005


Related references

Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia. BMJ Open Gastroenterology 5(1): E000209, 2018

Effectiveness and Tolerability of Direct Acting Antiviral Therapy for Hepatitis C in a Real World Elderly Cohort. Clinical Gastroenterology and Hepatology 15(4): 603-604, 2016

Real-World Effectiveness of All-Oral Direct Acting Antiviral Therapy in 5,763 Hepatitis C Genoype 2 and Genotype 3 Patients. Gastroenterology 154(6): S-1105, 2018

Real World Effectiveness of Sofosbuvir/velpatasvir/voxilaprevir in 573 Direct-Acting Antiviral Experienced Hepatitis C Patients. Journal of Viral Hepatitis 2019, 2019

Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. Journal of Antimicrobial ChemoTherapy 73(1): 160-164, 2017

Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. Journal of Gastroenterology 2018, 2018

Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine 96(6): E6128, 2017

Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection. Permanente Journal 21, 2017

Real-world Australian data reflect very high sustained virologic response at 12 weeks with direct acting antiviral therapy for hepatitis C and suggests highly achievable even in those without an end-of-treatment response. Internal Medicine Journal 49(5): 666-669, 2019

Chronic Hepatitis C Treatment with Direct-Acting Antiviral Agents in a Real-Life Setting. Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 68(4): 203-212, 2017

Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study. Bmc Psychiatry 18(1): 157, 2018

Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience. Journal of Viral Hepatitis 25(11): 1287-1297, 2018

Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV/Hepatitis C co-infected individuals. Journal of Viral Hepatitis 25(12): 1507-1514, 2018

Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. Journal of Hepatology 66(6): 1138-1148, 2017

Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience. Journal of Viral Hepatitis 24(11): 927-935, 2017